These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 24885608)

  • 1. Extraordinary response to crizotinib in a woman with squamous cell lung cancer after two courses of failed chemotherapy.
    Wang Q; He Y; Yang X; Wang Y; Xiao H
    BMC Pulm Med; 2014 May; 14():83. PubMed ID: 24885608
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Responses to crizotinib in patients with ALK-positive lung adenocarcinoma who tested immunohistochemistry (IHC)-positive and fluorescence in situ hybridization (FISH)-negative.
    Ma D; Wang Z; Yang L; Mu X; Wang Y; Zhao X; Li J; Lin D
    Oncotarget; 2016 Sep; 7(39):64410-64420. PubMed ID: 27418132
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined Pan-HER and ALK/ROS1/MET Inhibition with Dacomitinib and Crizotinib in Advanced Non-Small Cell Lung Cancer: Results of a Phase I Study.
    Jänne PA; Shaw AT; Camidge DR; Giaccone G; Shreeve SM; Tang Y; Goldberg Z; Martini JF; Xu H; James LP; Solomon BJ
    J Thorac Oncol; 2016 May; 11(5):737-747. PubMed ID: 26899759
    [TBL] [Abstract][Full Text] [Related]  

  • 4. First line crizotinib in anaplastic lymphoma kinase (ALK) rearranged squamous cell lung cancer.
    Mikes RE; Jordan F; Hutarew G; Studnicka M
    Lung Cancer; 2015 Dec; 90(3):614-6. PubMed ID: 26519123
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sequential Therapy with Crizotinib and Alectinib in ALK-Rearranged Non-Small Cell Lung Cancer-A Multicenter Retrospective Study.
    Ito K; Hataji O; Kobayashi H; Fujiwara A; Yoshida M; D'Alessandro-Gabazza CN; Itani H; Tanigawa M; Ikeda T; Fujiwara K; Fujimoto H; Kobayashi T; Gabazza EC; Taguchi O; Yamamoto N
    J Thorac Oncol; 2017 Feb; 12(2):390-396. PubMed ID: 27498387
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is there a progression-free survival benefit of first-line crizotinib versus standard chemotherapy and second-line crizotinib in ALK-positive advanced lung adenocarcinoma? A retrospective study of Chinese patients.
    Cui S; Zhao Y; Dong L; Gu A; Xiong L; Qian J; Zhang W; Niu Y; Pan F; Jiang L
    Cancer Med; 2016 Jun; 5(6):1013-21. PubMed ID: 26880708
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial.
    Shaw AT; Kim TM; Crinò L; Gridelli C; Kiura K; Liu G; Novello S; Bearz A; Gautschi O; Mok T; Nishio M; Scagliotti G; Spigel DR; Deudon S; Zheng C; Pantano S; Urban P; Massacesi C; Viraswami-Appanna K; Felip E
    Lancet Oncol; 2017 Jul; 18(7):874-886. PubMed ID: 28602779
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Response to crizotinib in a lung adenocarcinoma patient harboring EML4-ALK translocation with adnexal metastasis: A Case Report.
    Wang W; Wu W; Zhang Y
    Medicine (Baltimore); 2016 Jul; 95(30):e4221. PubMed ID: 27472693
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New insights into anaplastic lymphoma kinase-positive nonsmall cell lung cancer.
    Dubey AP; Pathi N; Viswanath S; Rathore A; Pathak A; Sud R
    Indian J Cancer; 2017; 54(1):203-208. PubMed ID: 29199691
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ALK-rearranged squamous cell lung carcinoma responding to crizotinib: A missing link in the field of non-small cell lung cancer?
    Vergne F; Quéré G; Andrieu-Key S; Descourt R; Quintin-Roué I; Talagas M; De Braekeleer M; Marcorelles P; Uguen A
    Lung Cancer; 2016 Jan; 91():67-9. PubMed ID: 26603857
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Whole-genome sequencing of an aggressive BRAF wild-type papillary thyroid cancer identified EML4-ALK translocation as a therapeutic target.
    Demeure MJ; Aziz M; Rosenberg R; Gurley SD; Bussey KJ; Carpten JD
    World J Surg; 2014 Jun; 38(6):1296-305. PubMed ID: 24633422
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EML4-ALK-positive non-small cell lung cancer in a patient treated with azathioprine for ulcerative colitis.
    Lazarev I; Sion-Vardy N; Ariad S
    Tumori; 2012; 98(4):e98-101. PubMed ID: 23052178
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.
    Kwak EL; Bang YJ; Camidge DR; Shaw AT; Solomon B; Maki RG; Ou SH; Dezube BJ; Jänne PA; Costa DB; Varella-Garcia M; Kim WH; Lynch TJ; Fidias P; Stubbs H; Engelman JA; Sequist LV; Tan W; Gandhi L; Mino-Kenudson M; Wei GC; Shreeve SM; Ratain MJ; Settleman J; Christensen JG; Haber DA; Wilner K; Salgia R; Shapiro GI; Clark JW; Iafrate AJ
    N Engl J Med; 2010 Oct; 363(18):1693-703. PubMed ID: 20979469
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characteristics, treatment patterns, and survival among ALK+ non-small cell lung cancer (NSCLC) patients treated with crizotinib: A chart review study.
    Cadranel J; Park K; Arrieta O; Pless M; Bendaly E; Patel D; Sasane M; Nosal A; Swallow E; Galebach P; Kageleiry A; Stein K; Degun R; Zhang J
    Lung Cancer; 2016 Aug; 98():9-14. PubMed ID: 27393500
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anaplastic lymphoma kinase gene rearrangements in patients with advanced-stage non-small-cell lung cancer: CT characteristics and response to chemotherapy.
    Park J; Yamaura H; Yatabe Y; Hosoda W; Kondo C; Shimizu J; Horio Y; Yoshida K; Tanaka K; Oguri T; Kobayashi Y; Hida T
    Cancer Med; 2014 Feb; 3(1):118-23. PubMed ID: 24403104
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Major partial response to crizotinib, a dual MET/ALK inhibitor, in a squamous cell lung (SCC) carcinoma patient with de novo c-MET amplification in the absence of ALK rearrangement.
    Schwab R; Petak I; Kollar M; Pinter F; Varkondi E; Kohanka A; Barti-Juhasz H; Schönleber J; Brauswetter D; Kopper L; Urban L
    Lung Cancer; 2014 Jan; 83(1):109-11. PubMed ID: 24192513
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A new human lung adenocarcinoma cell line harboring the EML4-ALK fusion gene.
    Isozaki H; Yasugi M; Takigawa N; Hotta K; Ichihara E; Taniguchi A; Toyooka S; Hashida S; Sendo T; Tanimoto M; Kiura K
    Jpn J Clin Oncol; 2014 Oct; 44(10):963-8. PubMed ID: 25170107
    [TBL] [Abstract][Full Text] [Related]  

  • 18. K-RAS mutations indicating primary resistance to crizotinib in ALK-rearranged adenocarcinomas of the lung: Report of two cases and review of the literature.
    Mengoli MC; Barbieri F; Bertolini F; Tiseo M; Rossi G
    Lung Cancer; 2016 Mar; 93():55-8. PubMed ID: 26898615
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Outcome of ALK-Positive Non-Small Cell Lung Cancer (NSCLC) Patients with De Novo EGFR or KRAS Co-Mutations Receiving Tyrosine Kinase Inhibitors (TKIs).
    Schmid S; Gautschi O; Rothschild S; Mark M; Froesch P; Klingbiel D; Reichegger H; Jochum W; Diebold J; Früh M
    J Thorac Oncol; 2017 Apr; 12(4):681-688. PubMed ID: 28007627
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Distribution of ALK Fusion Variants and Correlation with Clinical Outcomes in Chinese Patients with Non-Small Cell Lung Cancer Treated with Crizotinib.
    Su Y; Long X; Song Y; Chen P; Li S; Yang H; Wu P; Wang Y; Bing Z; Cao Z; Cao L; Wu Y; Zhang Z; Liu J; Li B; Xiang J; Ma K; Zhang T; Zhang L; Mao X; Liu H; Xing P; Liang N
    Target Oncol; 2019 Apr; 14(2):159-168. PubMed ID: 30895431
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.